Ausgabe 4/2003
Inhalt (12 Artikel)
In vivo antitumor activity of a novel sulfonamide, HMN-214, against human tumor xenografts in mice and the spectrum of cytotoxicity of its active metabolite, HMN-176
Manabu Takagi, Takuya Honmura, Shuuji Watanabe, Reiko Yamaguchi, Masaki Nogawa, Ikumi Nishimura, Fumitaka Katoh, Masato Matsuda, Hiroyoshi Hidaka
Biological role of adduct formation of the ruthenium(III) complex NAMI-A with serum albumin and serum transferrin
A. Bergamo, L. Messori, F. Piccioli, M. Cocchietto, G. Sava
Quinolizidinyl derivatives of iminodibenzyl and phenothiazine as multidrug resistance modulators in ovarian cancer cells
Federica Barbieri, Angela Alama, Bruno Tasso, Vito Boido, Cristina Bruzzo, Fabio Sparatore
Effect of novel benzoylphenylurea derivatives on DNA polymerase α activity using the synthesome-based in vitro model system
Waleed Abdel-Aziz, Robert Hickey, Martin Edelman, Linda Malkas
A study of a different dose-intense infusion schedule of phenylacetate in patients with recurrent primary brain tumors
Susan M. Chang, John G. Kuhn, H. Ian Robins, S. Clifford Schold, Alexander M. Spence, Mitchel S. Berger, Minesh P. Mehta, Ian Pollack, Mark Gilbert, Michael D. Prados
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism
Albert Font, José Miguel Sánchez, Miquel Tarón, Eva Martinez-Balibrea, José Javier Sánchez, José Luis Manzano, Mireia Margelí, Martin Richardet, Agustí Barnadas, Albert Abad, Rafael Rosell
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies
Robert Wieder, Steven C. Novick, Bruce W. Hollis, Margarette Bryan, Suzanne M. Chanel, Kate Owusu, Danielle Camastra, Tracie Saunders, Lillian Pliner, Jonathan Harrison, Peter Bonate, Tom Williams, Steven Soignet
A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study
Deborah K. Armstrong, John A. Blessing, Janet Rader, Joel I. Sorosky
Activity of weekly irinotecan (CPT-11) in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes
Rosa Sánchez, Emilio Esteban, Isabel Palacio, Yolanda Fernández, Isabel Muñiz, Jose M. Vieitez, Joaquin Fra, Pilar Blay, Noemí Villanueva, Esther Uña, Beatriz Mareque, Enrique Estrada, Jose M. Buesa, Angel J. Lacave
A phase II study of rebeccamycin analog (NSC-655649) in metastatic renal cell cancer
Maha Hussain, Ulka Vaishampayan, Lance K. Heilbrun, Vikash Jain, Patricia M. LoRusso, Percy Ivy, Lawrence Flaherty
A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma
Karl Bélanger, David MacDonald, Gregory Cairncross, Stan Gertler, Peter Forsyth, Susan Burdette-Radoux, Julie Bergeron, Denis Soulières, Samuel Ludwin, Nancy Wainman, Elizabeth Eisenhauer
An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma
Peter Reichardt, Karin Oechsle, Daniel Pink, Carsten Bokemeyer, F. Schneller, Rolf Issels, Lothar Kanz, Jörg Thomas Hartmann